We are monitoring the impact of COVID-19 on MEA Biologics Market Get in touch with us for detailed analysis Know More
Share on

Middle East & Africa Biologics Market Research Report – Segmented By Source, Product, Biologics Manufacturing Type, Disease Category and Country (KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA) – Industry Size, Share, Trends, Growth & Forecast (2022 to 2027)

Published: January, 2022
ID: 11721
Pages: 90

MEA Biologics Market Size (2022 to 2027)

The Middle East & Africa biologics market size is expected to showcase a healthy growth rate during the forecast period.

MARKET DRIVERS:

There is an increase in High Throughput Screening (HTS) technology in the Middle East and Africa for various drug development processes. The technology is used to identify threads to discover an inhibitor of Middle East Respiratory Syndrome (MERS). This factor is attributed to fuel the growth rate of the biologics market in the MEA region. The increasing prevalence of diseases such as AIDS, Alzheimer's disease, and other drug-resistant infectious diseases has also led to the discovery new bioactive compounds that are likely to boost the market's growth rate.

Supply management for clinical trials is necessary to avoid overproduction, oversupply, and expiration of stocks. With the rising costs of drug discovery, supplies for clinical trials are gaining in importance. Hence a subsequent increase in the market for biologics.

MARKET RESTRAINTS:

Biologic drugs are very complex and must be controlled and maintained throughout the development and production process. This regulated environment and these quality control procedures involve significant capital investment in the initial phase of the process. In addition, biologics products are more sensitive to light and hot conditions and require an extremely promising environment that is not uniformly available globally.

In most emerging markets today, biologics products are scarce. Strict regulatory policies and high capital investments, coupled with limited patient access to biologics, mainly in developing countries, due to increased control and the cost of access to biologics, are likely to 'hamper the growth of the biologics market in the Middle East and Africa in the coming years.

Impact of COVID-19 on the MEA biologics market:

Since the increase in COVID-19 cases, the pharmaceutical industry has decreased its production capacity, leading to drug shortages. In addition, the diversion of resources from drug development to treatment for coronaviruses is likely to hamper the overall productivity of drug development for a short period of time.

Several pharmaceutical companies have decided to postpone ongoing clinical R&D due to disrupted supply chains and the threat of the virus. The Middle East is struggling to control the crisis due to the limited supply of health care due to the sanctions imposed by the United States on the country.

Such restrictions are likely to have a negative impact on research and development activities, directly limiting the growth of the biologics products market in the Middle East and Africa.

This research report on the MEA Biologics Market has been segmented & sub-segmented into the following categories:

By Source:  

  • Microbial
  • Mammalian
  • Others

By Product:

  • Monoclonal Antibodies
  • Vaccines
  • Recombinant Proteins
  • Antisense, RNAi, & Molecular Therapy
  • Others

By Biologics Manufacturing:

  • Outsourced
  • In-house

By Disease Category:

  • Oncology
  • Infectious Diseases
  • Immunological Disorders
  • Cardiovascular Disorders
  • Hematological Disorders
  • Others

By Country:

  • KSA
  • UAE
  • Israel
  • rest of GCC countries
  • South Africa
  • Ethiopia
  • Kenya
  • Egypt
  • Sudan
  • rest of MEA

Geographically, the South African biologics market is estimated to be the most lucrative regional market in the MEA and is expected to register a promising growth rate during the forecast period. South Africa has started to focus on developing new drugs for progressive diseases. Due to the increase in acute and chronic diseases, the demand for small molecule therapies is increasing in the country. The Biosciences Unit of the Council for Scientific and Industrial Research (CSIR) is carrying out a large collaborative malaria research project with the help of biologics technology. Various public-private foundations fund the project, and more than 50 scientists contribute to the research project at various universities and research institutes in South Africa.

The UAE biologics market is another lucrative regional market and is predicted to showcase a healthy CAGR from 2022 to 2027. The country is dedicated to putting in place the necessary initiatives and infrastructure that could help develop the pharmaceutical value chain, which includes HTS, medical chemistry, and preclinical testing. This would increase drug biologics procedures, increase partnerships between companies and government organizations in the country to implement the process, and thus create wide opportunities for growth in the biologics market. These factors propel the demand of the market.

KEY MARKET PLAYERS:

A few prominent companies operating in the MEA biologics market profiled in this report are Johnson & Johnson (J&J), F Hoffmann-La Roche, Bristol-Myers Squibb, GlaxoSmithKline, AbbVie, Amgen, Sanofi, Eli Lilly and Company, Merck & Co., and Pfizer Inc.

  1. Introduction
    1. Market Definition
    2. Study Deliverables
    3. Base Currency, Base Year and Forecast Periods
    4. General Study Assumptions
  2. Research Methodology
    1. Introduction
    2. Research Phases
      1. Secondary Research
      2. Primary Research
      3. Econometric Modelling
      4. Expert Validation
    3. Analysis Design
    4. Study Timeline
  3. Overview
    1. Executive Summary
    2. Key Inferences
    3. New Developments
  4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
    1. Market Drivers
    2. Market Restraints
    3. Key Challenges
    4. Current Opportunities in the Market
  5. Market Segmentation
    1. By Source
      1. Microbial
      2. Mammalian
      3. Others
    2. By Product
      1. Monoclonal Antibodies
      2. Vaccines
      3. Recombinant Proteins
      4. Antisense, RNAi, & Molecular Therapy
      5. Others
    3. By Biologics Manufacturing
      1. Outsourced
      2. In-house
    4. By Disease Category
      1. Oncology
      2. Infectious Diseases
      3. Immunological Disorders
      4. Cardiovascular Disorders
      5. Hematological Disorders
      6. Others
  6. Geographical Analysis
    1. Introduction    
      1. Regional Trends   
      2. Impact Analysis    
      3. Y-o-Y Growth Analysis        
        1. By Geographical Area
        2. By Product
        3. By Technology
        4. By Application
        5. By End-User
      4. Market Attractiveness Analysis      
        1. By Geographical Area
        2. By Product
        3. By Technology
        4. By Application
        5. By End-User
      5.      Market Share Analysis   
        1. By Geographical Area
        2. By Product
        3. By Technology
        4. By Application
        5. By End-User
    2. Middle East and Africa
      1. Introduction
      2. Middle East
      3. Africa
  7. Strategic Analysis
    1. PESTLE analysis
      1. Political
      2. Economic
      3. Social
      4. Technological
      5. Legal
      6. Environmental
    2. Porter’s Five analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Consumers
      3. Threat of New Entrants
      4. Threat of Substitute Products and Services
      5. Competitive Rivalry within the Industry
  8. Market Leaders' Analysis
    1. Johnson & Johnson (J&J)
      1. Overview
      2. Product Analysis
      3. Strategic Evaluation and Operations
      4. Financial analysis
      5. Legal issues
      6. Recent Developments
      7. SWOT analysis
      8. Analyst View
    2. F Hoffmann-La Roche
    3. Bristol-Myers Squibb
    4. GlaxoSmithKline
    5. AbbVie
    6. Amgen
    7. Sanofi
    8. Eli Lilly and Company
    9. Merck & Co.
    10. Pfizer
  9. Competitive Landscape
    1. Market share analysis
    2. Merger and Acquisition Analysis
    3. Agreements, Collaborations and Joint Ventures
    4. New Product Launches
  10. Market Outlook and Investment Opportunities
  11. Appendix
    1. List of Tables
    2. List of Figures  
  1. Middle East and Africa Biologics Market, By Source, From 2022 - 2027 (USD Billion)
  2. Middle East and Africa Microbial Market, By Region, From 2022 - 2027 (USD Billion)
  3. Middle East and Africa Mammalian Market, By Region, From 2022 - 2027 (USD Billion)
  4. Middle East and Africa Others Market, By Region, From 2022 - 2027 (USD Billion)
  5. Middle East and Africa Biologics Market, By Product, From 2022 - 2027 (USD Billion)
  6. Middle East and Africa Monoclonal Antibodies Market, By Region, From 2022 - 2027 (USD Billion)
  7. Middle East and Africa Vaccines Market, By Region, From 2022 - 2027 (USD Billion)
  8. Middle East and Africa Recombinant Proteins Market, By Region, From 2022 - 2027 (USD Billion)
  9. Middle East and Africa Antisense, RNAi, & Molecular Therapy Market, By Region, From 2022 - 2027 (USD Billion)
  10. Middle East and Africa Others Market, By Region, From 2022 - 2027 (USD Billion)
  11. Middle East and Africa Biologics Market, By Biologics Manufacturing, From 2022 - 2027 (USD Billion)
  12. Middle East and Africa Outsourced Market, By Region, From 2022 - 2027 (USD Billion)
  13. Middle East and Africa In-house Market, By Region, From 2022 - 2027 (USD Billion)
  14. Middle East and Africa Biologics Market, By Disease Category, From 2022 - 2027 (USD Billion)
  15. Middle East and Africa Oncology Market, By Region, From 2022 - 2027 (USD Billion)
  16. Middle East and Africa Infectious Diseases Market, By Region, From 2022 - 2027 (USD Billion)
  17. Middle East and Africa Immunological Disorders Market, By Region, From 2022 - 2027 (USD Billion)
  18. Middle East and Africa Cardiovascular Disorders Market, By Region, From 2022 - 2027 (USD Billion)
  19. Middle East and Africa Hematological Disorders Market, By Region, From 2022 - 2027 (USD Billion)
  20. Middle East and Africa Others Market, By Region, From 2022 - 2027 (USD Billion)
  21. Middle East Biologics Market, By Source, From 2022 - 2027 (USD Billion)
  22. Middle East Biologics Market, By Product, From 2022 - 2027 (USD Billion)
  23. Middle East Biologics Market, By Biologics Manufacturing, From 2022 - 2027 (USD Billion)
  24. Middle East Biologics Market, By Disease Category, From 2022 - 2027 (USD Billion)
  25. Africa Biologics Market, By Source, From 2022 - 2027 (USD Billion)
  26. Africa Biologics Market, By Product, From 2022 - 2027 (USD Billion)
  27. Africa Biologics Market, By Biologics Manufacturing, From 2022 - 2027 (USD Billion)
  28. Africa Biologics Market, By Disease Category, From 2022 - 2027 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

PURCHASE OPTIONS

excel
$

3335


pdf excel
$

3680


pdf excel powerbi
$

5520


excel
$

2000

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • 6 Months of Free Analyst Support.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • 1 Year of Free Analyst Support.
  • PDF, Excel and Power BI Dashboard.
  • Can be accessible by unlimited users.
  • 1 Year of Free Analyst Support.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
customer-support
ASK FOR CUSTOMIZATION

Talk to our analyst and get customised report done according to your research needs

tag
INQUIRE FOR DISCOUNT

Check if you can avail any discount. Submit your details and our team will get back to you.

cloud-download
DOWNLOAD FREE SAMPLE

Request to avail a free sample report that reflects this market and its growth.

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 3335

Didn’t find what you’re looking for?
TALK TO OUR TEAM

Find it too expensive?
NO WORRIES!

Click for Request Sample